The FY23 Defense Appropriations Act provides funding for the Lung Cancer Research Program to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men.
